Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab consolidation therapy in chronic lymphocytic leukemia
ISRCTN64035629Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Obinutuzumab consolidation with Observation / no consolidation (2 arms). Primary endpoint: Progression-free survival. Started Feb 2015; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN64035629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64035629.